Edition:
United States

Innate Pharma SA (IPH.PA)

IPH.PA on Paris Stock Exchange

10.87EUR
10:29am EDT
Change (% chg)

€-0.22 (-1.98%)
Prev Close
€11.09
Open
€11.13
Day's High
€11.13
Day's Low
€10.87
Volume
75,958
Avg. Vol
240,482
52-wk High
€15.83
52-wk Low
€9.65

IPH.PA

Chart for IPH.PA

About

Innate Pharma SA is a France-based biopharmaceutical Company that develops drugs for treatment of cancer and inflammatory diseases. The Company identifies and characterizes drug candidates, selects indications and manages the pre-clinical and clinical development of products. Innate Pharma primarily focuses on the development of... (more)

Overall

Beta: 1.19
Market Cap(Mil.): €636.08
Shares Outstanding(Mil.): 57.36
Dividend: --
Yield (%): --

Financials

  IPH.PA Industry Sector
P/E (TTM): 47.28 211.50 15.59
EPS (TTM): 0.23 -- --
ROI: 5.61 -8.04 -8.43
ROE: 15.98 -9.41 -8.00

BRIEF-Innate Pharma issues 3,343,748 ordinary shares

* REG-ISSUANCE BY INNATE PHARMA OF 3,343,748 ORDINARY SHARES TO NOVO NORDISK A/S IN CONSIDERATION FOR RIGHTS IN ANTI-C5AR

Jul 13 2017

BRIEF-Innate Pharma to list 3,343,748 new ordinary shares - Euronext‍​

* INNATE PHARMA TO LIST 3,343,748 NEW ORDINARY SHARES AS OF JULY 17 FOLLOWING CAPITAL INCREASE BY CONTRIBUTION FURTHER COMPANY COVERAGE: (Gdynia Newsroom:)

Jul 13 2017

BRIEF-Innate Pharma dose-escalation data show favorable safety profile

* REG-INNATE PHARMA : DOSE-ESCALATION DATA SHOW FAVORABLE SAFETY PROFILE AND PROMISING CLINICAL ACTIVITY FOR IPH4102 Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Jun 15 2017

BRIEF-Innate Pharma acquires anti-c5ar from Novo Nordisk A/S

* Innate Pharma acquires anti-c5ar, a first-in-class clinical-stage antibody, from Novo Nordisk A/S

Jun 02 2017

BRIEF-Innate Pharma acquires anti-C5aR from Novo Nordisk

* Innate Pharma acquires anti-C5aR, a first-in-class clinical-stage antibody, from Novo Nordisk A/S

Jun 02 2017

BRIEF-Innate Pharma completed the dose escalation part of its ongoing phase I trial

* COMPLETED THE DOSE ESCALATION PART OF ITS ONGOING PHASE I TRIAL EVALUATING IPH4102 IN PATIENTS WITH RELAPSED/REFRACTORY CUTANEOUS T CELL LYMPHOMAS

May 22 2017

BRIEF-Innate Pharma Q1 revenue up at EUR 7.3 mln

* CASH, CASH EQUIVALENTS AND FINANCIAL ASSETS AT MARCH 31 AMOUNT TO EUR 223.8 MLN

May 15 2017

BRIEF-Innate Pharma expands Phase I/II trial testing lirilumab with Opdivo

* Announces the expansion of Phase I/II trial evaluating lirilumab in combination with Opdivo Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Mar 13 2017

CORRECTED-BRIEF-Innate Pharma FY operating result turns to profit of 7.6 million euros

* Cash and cash equivalents at December 31, 2016 230.7 million euros ($244.47 million) versus 273.7 million euros year ago

Mar 07 2017

BRIEF-Innate Pharma: Cash and cash equivalents at Dec. 31, 2016 of 230.7 million euros

* Cash and cash equivalents at Dec. 31, 2016 230.7 million euros ($244.27 million) versus 152.9 million euros year ago

Mar 07 2017

Earnings vs. Estimates